PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 30, 2026Cancers0 citationsOpen Access

CRLF1 Drives Prostate Cancer Progression via COMP-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway

View Full Paper
ZLZhongze LiJWJinrun WangLXLizhe Xu

Key Points

  • The investigation aimed to clarify the role and mechanisms of CRLF1 in prostate cancer progression.
  • Conducted bioinformatics analyses using TCGA-PRAD dataset
  • Validated CRLF1 and COMP levels through qRT-PCR and Western blot
  • Performed in vitro functional assessments and utilized a xenograft tumor model for in vivo validation.
  • CRLF1 and COMP levels were significantly higher in prostate cancer tissues compared to benign tissues.
  • Silencing CRLF1 reduced cancer cell growth and invasion, and increased apoptosis.
  • CRLF1 activates the FAK/PI3K/AKT signaling pathway through COMP to promote tumor progression.

Abstract

Background: Cytokine-like receptor family 1 (CRLF1) has been implicated in tumor progression, yet its prognostic function and mechanistic actions in prostate cancer (PCa) remain elusive. Objective: This investigation sought to clarify the functional role, molecular mechanisms, and clinical relevance of CRLF1 in the progression of PCa. Methods: We conducted extensive bioinformatics analyses utilizing the protein interaction networks and the TCGA-PRAD dataset. CRLF1 and cartilage oligomeric matrix protein (COMP) expression were validated in clinical samples by qRT-PCR and Western blot (WB). Functional assessments, including Transwell invasion, flow cytometry, CCK-8, and wound healing, were conducted in vitro. An in vivo xenograft tumor model was used for further validation. Mechanistic investigations involved genetic perturbation (overexpression and inhibition) of CRLF1 and COMP. Results: Compared to benign tissues, the levels of CRLF1 and COMP were markedly elevated in PCa tissues. Bioinformatics assessments illustrated a robust positive relationship between CRLF1 and COMP, suggesting COMP may function as a downstream mediator. In vitro and in vivo investigations illustrated that silencing CRLF1 significantly suppressed PCa cell growth, invasion, and tumor progression, while enhancing apoptosis. Importantly, suppressing COMP counteracted the cancer-promoting effects triggered by CRLF1 overexpression. At the mechanistic level, CRLF1 facilitates tumor progression by modulating COMP to activate the FAK/PI3K/AKT signaling cascade. Conclusions: Our outcomes demonstrate that CRLF1 promotes PCa progression by targeting COMP to stimulate the FAK/PI3K/AKT signaling axis. This newly identified CRLF1/COMP/FAK/PI3K/AKT pathway underscores CRLF1 as a potential biomarker and therapeutic target for PCa.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69f2f1771e5f7920c638726ehttps://doi.org/10.3390/cancers18091395
Ask AI
Helpful
Bookmark
Share
View Full Paper